BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Checkpoint inhibitors
1
Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?
11/12/2024 12:23:36 PM | Browse: 96 | Download: 458
2
Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept
4/24/2024 8:35:39 AM | Browse: 115 | Download: 476
3
Implication of gut microbiome in immunotherapy for colorectal cancer
9/9/2022 12:48:14 PM | Browse: 565 | Download: 1629
4
Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach
7/27/2022 1:17:37 PM | Browse: 478 | Download: 1197
5
Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma
1/22/2022 6:17:12 AM | Browse: 624 | Download: 1331
6
Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
7/6/2019 6:23:58 AM | Browse: 1465 | Download: 2601
7
Checkpoint inhibitors: What gastroenterologists need to know
12/27/2018 8:56:32 AM | Browse: 936 | Download: 1603
8
Drug resistance and new therapies in colorectal cancer
9/14/2018 5:53:04 AM | Browse: 1293 | Download: 1824
9
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
8/8/2017 1:51:46 AM | Browse: 1150 | Download: 1939
10
Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality
5/6/2017 8:30:21 PM | Browse: 1161 | Download: 1818
11
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis
2/8/2017 3:24:00 PM | Browse: 1202 | Download: 1849